Korean J Med Mycol.  1997 Dec;2(2):110-122.

Systemic Antifungal Agents

Affiliations
  • 1Department of Internal Medicine, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea.

Abstract

There is an increasing tendency of systemic fungal infection because of increase in the number of immunocomproised patients such as the patients receiving anticancer chmotherapy or organ transplant. The frequency of systemic fungal infection is problematic, since it is often difficult for clinicians to manage the patients with fungal infection. Amphotericin B was one of the representativ antifungal agent for the systemic antifungal infection even though it has many kinds of advers reactions for instance nephrotoxicity, electrolyte imbalance, etc. Therefore ketoconazole, fluconazole, and itraconazole were develped and prescribed with effect. Because of increase in the number of resistant strains of Candida, Fusarium or Trichosporon nowadays, as for azole antifungal agents there were something to be desired. Other new antifungal agents with fungicidal effect under develpment include polyoxins, echinocandins and pradimicin.

Keyword

Systemic antifungal agents

MeSH Terms

Amphotericin B
Antifungal Agents*
Candida
Danazol
Echinocandins
Fluconazole
Fusarium
Humans
Itraconazole
Ketoconazole
Transplants
Trichosporon
Amphotericin B
Antifungal Agents
Danazol
Echinocandins
Fluconazole
Itraconazole
Ketoconazole
Full Text Links
  • KJMM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr